Vonoprazan‐Based Triple Therapy Versus Esomeprazole‐Based Triple Therapy for H. pylori Eradication in Adolescents ( VONTAPE ): A Randomized, Double‐Blind Controlled Trial
Helicobacter · 2025
DOI: 10.1111/hel.70083 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, 2025. Verfasst von Sameh A Lashen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine (Gastroenterology and Hepatology Division), Faculty of Medicine, Alexandria University, Alexandria, Egypt. Hauptthemen laut MEDLINE: Helicobacter Infections, Sulfonamides, Esomeprazole, Pyrroles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Background and Aim While H. pylori infection is more commonly associated with adults, it can affect children with an impact on their well‐being. Vonoprazan is effective in the eradication of H. pylori infection in adults. However, its effectiveness in adolescents and children is still being studied. The study aimed to investigate the efficacy of Vonoprazan‐based triple therapy (VTT) compared to Esomeprazole‐based triple therapy (ETT) for H. pylori eradication in adolescents and children. Patients and Methods In a multicenter, double‐blind, randomized controlled design, we included 242 participants with H. pylori infection in the age group 10–18 years. They were randomly assigned to either weight‐based Esomeprazole/Amoxicillin/Clarithromycin twice daily for 14 days (ETT) or to Vonoprazan 20 mg/weight‐based Amoxicillin/Clarithromycin twice daily for 14 days (VTT). The H. pylori eradication was evaluated 8 weeks after therapy. Treatment‐related adverse events were reported.
Results
In intention‐to‐treat analysis, eradication of H. pylori was achieved in 93 (76.9%) of the ETT arm and in 106 (87.6%) of the VTT arm ( p = 0.029). In per‐protocol analysis, eradication rates were 83% and 92.2% for ETT and VTT, respectively ( p = 0.036). There was no difference between the two study arms in terms of overall adverse events ( p = 0.46). In the VTT arm, the most frequent adverse events were diarrhea (5.8%) and nausea (6.6%).
Conclusion
Fourteen days of VTT is superior to ETT for H. pylori eradication and is well tolerated in children and adolescents aged between 10 and 18 years. Clinical Trial Registry NCT06162949; https://clinicaltrials.gov/study/NCT06162949 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine (Gastroenterology and Hepatology Division), Faculty of Medicine, Alexandria University, Alexandria, Egypt.
- Department of Clinical and Experimental Internal Medicine, Medical Research Institute, Alexandria University, Alexandria, Egypt.
- Department of Pediatrics, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
- Department of Hepatology, Gastroenterology, and Infectious Diseases, Faculty of Medicine, Azhar University, Cairo, Egypt.
ORCID-Profile: Sameh A Lashen
Zitieren
APA
Lashen, S. A., Shamseyea, M. M., Metwally, R. H., Abou-Farrag, G., & Elkaragy, E. S. (2025). Vonoprazan‐Based Triple Therapy Versus Esomeprazole‐Based Triple Therapy for H. pylori Eradication in Adolescents ( VONTAPE ): A Randomized, Double‐Blind Controlled Trial. Helicobacter. https://doi.org/10.1111/hel.70083
Vancouver
Lashen SA, Shamseyea MM, Metwally RH, Abou-Farrag G, Elkaragy ES. Vonoprazan‐Based Triple Therapy Versus Esomeprazole‐Based Triple Therapy for H. pylori Eradication in Adolescents ( VONTAPE ): A Randomized, Double‐Blind Controlled Trial. Helicobacter. 2025. doi:10.1111/hel.70083
BibTeX
@article{Lashen2025,
author = {Lashen, Sameh A and Shamseyea, Mohammed M and Metwally, Rasha H and Abou-Farrag, Galal and Elkaragy, Engy S},
title = {Vonoprazan‐Based Triple Therapy Versus Esomeprazole‐Based Triple Therapy for H. pylori Eradication in Adolescents ( VONTAPE ): A Randomized, Double‐Blind Controlled Trial},
journal = {Helicobacter},
year = {2025},
doi = {10.1111/hel.70083}
}
EUVIMED